Clinical predictors of disease progression in a cohort of Tunisian progressive Multiple Sclerosis.


Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
Nov 2021
Historique:
received: 17 06 2021
revised: 11 08 2021
accepted: 29 08 2021
pubmed: 8 10 2021
medline: 17 12 2021
entrez: 7 10 2021
Statut: ppublish

Résumé

Knowledge about progressive Multiple Sclerosis (MS) is mainly based on Caucasian studies. In our North-African context, MS exhibits particular characteristics that are mainly related to a more severe phenotype. Given the limited data available, there is an imminent need to characterize progressive MS in our latitudes. To describe the specificities of progressive MS and identify the inherent clinical predictors of disability accrual with a Tunisian cohort. A retrospective, hospital-based study was conducted in the department of neurology of Razi hospital. Patients, who had been diagnosed with MS, were divided into relapsing MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS). Epidemiological, clinical and paraclinical data were compared among the three groups. Of the 504 patients, a progressive MS was described among 115 patients. This percentage of (22.8%) is divided into 13.9% SPMS and 8.9% PPMS. During the first clinical attack, motor symptoms have revealed to be predominant during PPMS (91.1%). For SPMS onset, the median time was 10 years, and was significantly delayed for patients with visual onset or full recovery from the first relapse. Patients with progressive MS exhibited a more rapid disability accumulation. Compared to Caucasians, Tunisians exhibited a faster rate of conversion to SPMS. According to our natural progressive MS history, early clinical features are predictors of MS disability accrual.

Sections du résumé

BACKGROUND BACKGROUND
Knowledge about progressive Multiple Sclerosis (MS) is mainly based on Caucasian studies. In our North-African context, MS exhibits particular characteristics that are mainly related to a more severe phenotype. Given the limited data available, there is an imminent need to characterize progressive MS in our latitudes.
OBJECTIVE OBJECTIVE
To describe the specificities of progressive MS and identify the inherent clinical predictors of disability accrual with a Tunisian cohort.
METHODS METHODS
A retrospective, hospital-based study was conducted in the department of neurology of Razi hospital. Patients, who had been diagnosed with MS, were divided into relapsing MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS). Epidemiological, clinical and paraclinical data were compared among the three groups.
RESULTS RESULTS
Of the 504 patients, a progressive MS was described among 115 patients. This percentage of (22.8%) is divided into 13.9% SPMS and 8.9% PPMS. During the first clinical attack, motor symptoms have revealed to be predominant during PPMS (91.1%). For SPMS onset, the median time was 10 years, and was significantly delayed for patients with visual onset or full recovery from the first relapse. Patients with progressive MS exhibited a more rapid disability accumulation.
CONCLUSION CONCLUSIONS
Compared to Caucasians, Tunisians exhibited a faster rate of conversion to SPMS. According to our natural progressive MS history, early clinical features are predictors of MS disability accrual.

Identifiants

pubmed: 34619488
pii: S2211-0348(21)00499-5
doi: 10.1016/j.msard.2021.103232
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

103232

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

A Souissi (A)

Department of Neurology, LR 18SP03, Clinical Investigation Centre Neurosciences and Mental Health, Razi Universitary Hospital, Manouba, Tunis, Tunisia.

S Mrabet (S)

Department of Neurology, LR 18SP03, Clinical Investigation Centre Neurosciences and Mental Health, Razi Universitary Hospital, Manouba, Tunis, Tunisia; Faculty of medicine, University Tunis El Manar, 1007, Tunis, Tunisia.

A Nasri (A)

Department of Neurology, LR 18SP03, Clinical Investigation Centre Neurosciences and Mental Health, Razi Universitary Hospital, Manouba, Tunis, Tunisia; Faculty of medicine, University Tunis El Manar, 1007, Tunis, Tunisia.

M Ben Djebara (M)

Department of Neurology, LR 18SP03, Clinical Investigation Centre Neurosciences and Mental Health, Razi Universitary Hospital, Manouba, Tunis, Tunisia; Faculty of medicine, University Tunis El Manar, 1007, Tunis, Tunisia.

A Gargouri (A)

Department of Neurology, LR 18SP03, Clinical Investigation Centre Neurosciences and Mental Health, Razi Universitary Hospital, Manouba, Tunis, Tunisia; Faculty of medicine, University Tunis El Manar, 1007, Tunis, Tunisia.

I Kacem (I)

Department of Neurology, LR 18SP03, Clinical Investigation Centre Neurosciences and Mental Health, Razi Universitary Hospital, Manouba, Tunis, Tunisia; Faculty of medicine, University Tunis El Manar, 1007, Tunis, Tunisia.

R Gouider (R)

Department of Neurology, LR 18SP03, Clinical Investigation Centre Neurosciences and Mental Health, Razi Universitary Hospital, Manouba, Tunis, Tunisia; Faculty of medicine, University Tunis El Manar, 1007, Tunis, Tunisia. Electronic address: riadh.gouider@gnet.tn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH